Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Let Go of 10,000 Shares?
Focused on innovative cancer therapies, this biotech saw a notable insider sale amid a year of strong share price gains.
Overview
Mark Schoenberg, Chief Medical Officer of UroGen Pharma Ltd. (NASDAQ:URGN), reported the sale of 10,000 shares of common stock in an open-market transaction on June 22, 2026, according to a SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average purchase price ($35.01); post-transaction value based on June 22, 2026, market close ($34.99).
Details
* 1-year performance calculated using June 30, 2026, as the reference date.
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.